Hundreds of flawed coronavirus clinical trials amount to 'wasted' effort and energy, experts say

Hydroxychloroquine.
(Image credit: GEORGE FREY/AFP via Getty Images)

If you've followed coronavirus research developments since the pandemic began, you're probably aware there have been quite a few clinical trials and studies aimed at finding a treatment or prevention for COVID-19. In fact, Stat News reports there have been 1,200 designed since January, which is a remarkable number in such a short amount of time. The problem is a lot of them are fatally flawed, a new analysis conducted by Stat found.

Robert Califf, the head of clinical policy and strategy at Verily Life Sciences and Google Health who previously served as commissioner for the Food and Drug Administration, said the analysis shows many studies are too small to answer questions (39 percent are enrolling or plan to enroll fewer than 100 patients), lack real control groups, and emphasized a few potential treatments (one out of every six focused on the President Trump-favored malaria drugs, hydroxychloroquine and chloroquine) too frequently. "If the goal was to optimize the likelihood of figuring out the best treatment options, the system is off course," he told Stat.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
Explore More
Tim O'Donnell

Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.